Trials in chronic skin ulcers using new collagen substitutes incorporating basic fibroblast growth factor

Trials in chronic skin ulcers using new collagen substitutes incorporating basic fibroblast growth factor - Trials in chronic skin ulcers using new collagen substitutes incorporating basic fibroblast growth factor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003404

Enrollment

Registered

2010-04-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic skin ulcers

Interventions

Application of artificial dermis (7microgram/ cm2 of trafermin) Application of artificial dermis (14microgram/ cm2 of trafermin)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient's ulcer has been present for a minimum of 1 month 2. Maximum area of ulcer is within 70mmx100mm 3.Skin Perfusion Pressure at the proximal margin or distal margin of patient's ulcer(existing in lower extremity) is more than 30mmHg. 4.age: =>20 5. patients providing written informed consent

Exclusion criteria

Exclusion criteria: 1.Decubitus with pocket 2.Patient's ulcer is with extensive exposure of tendon or bone 3.Ulcer with a infection

Design outcomes

Primary

Measure	Time frame
Improvement of wound 2 weeks after implantation	—

Secondary

Measure	Time frame
1.adverse event 2.wound area 3.granulation area	—

Countries

Japan

Contacts

Public ContactNaoki Morimoto

Kyoto University Hospital department of Plastic and Reconstructive surgery

075-751-4460

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026